No Data
Novo-Nordisk A/S experienced its largest monthly decline in over 20 years, the long-term outlook remains Bullish, but the short-term rebound is weak.
①The Danish weight-loss drug giant Novo-Nordisk A/S has recorded its worst monthly performance in over twenty years; although Analysts remain Bullish on the stock's long-term prospects, there is a lack of catalysts expected to stimulate a rebound in the stock price in the short term. ② Since hitting an all-time high last June, the share price of Novo-Nordisk A/S has faced multiple setbacks.
Novo Nordisk Had Constructive Quarter, But U.S. Volumes a Concern -- Market Talk
Top Gap Ups and Downs on Monday: MUFG, UBS, MFG and More
Novo-Nordisk A/S plummeted 27% this month, marking the worst month since the Internet bubble, suffering a huge loss in Market Cap in the European stock market.
Novo-Nordisk A/S's stock price has plummeted over 27% this month, setting the worst single-month record since 2002. Since June last year, Novo-Nordisk A/S has faced a series of bearish developments, including the demand for weight-loss drugs Wegovy and Ozempic falling short of expectations, disappointing mid-term trial results for the oral weight-loss drug monlunabant, and poor data performance from another investigational injectable drug, CagriSema. However, Wall Street remains generally optimistic about the stock.
Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug
Novo Nordisk Gains Exclusive Rights to Lexicon's Non-incretin Obesity Drug Candidate
